Fig. 2.
H2B is an AMPK target. (A to D) In vitro phosphorylation by myc-AMPK immunoprecipitated from ampkα−/− MEFs of recombinant human histones by beads alone, WT myc-AMPK, or catalytic mutant (D157A) myc-AMPK (right: myc Western blot) (A); recombinant human histones using myc-AMPK from glucose-treated cells (+glucose) or untreated cells (−glucose) (B); H2B peptides (C); and H2B 21–42 and SAMS peptide (D). (E) Western blots of wild-type or ampkα−/− MEFs treated with 2-DG (25 mM for 10 min) or untreated. (F) Western blots of MEFs treated for 1 hour with AICAR (AIC, 2 mM) or phenformin (Ph, 3 mM) or untreated.